Bernard Zovighian on sales guidance
From Edwards Lifesciences Corp ($EW) Q3 2025 Earnings Call · · Castify Earnings Call
“We continue to expect our full year 2025 surgical global sales will be in the mid single digit driven by Resilia portfolio adoption across our key markets and growth in heart valve procedures for patients best treated surgically.”
On , Bernard Zovighian, Chief Executive Officer & Director at Edwards Lifesciences Corp, spoke about sales guidance during Edwards Lifesciences Corp ($EW) Q3 2025 Earnings Call on Castify Earnings Call.
About Bernard Zovighian
Bernard Zovighian, CEO of Edwards Lifesciences, discussed the company's third quarter 2025 financial results on an earnings call. He stated that based on strong Q3 performance, the company was raising its full-year sales growth guidance to the high end of a previous 9 to 10 percent range and raising its EPS guidance range to between $2.56 and $2.62. Zovighian also said the company was raising its full-year TAVR guidance to 7 to 8 percent from a previous 6 to 7 percent range, attributing the quarter's results to factors including a "halo" effect from recent clinical data and guidelines that made TAVR "at the center of a conversation" for heart teams, as well as a less pronounced summer seasonality than usual. Looking ahead, Zovighian said the company expects a good Q4, though he cautioned against taking the Q3 result as "the new normal" for TAVR. He reiterated that Edwards expects to deliver sustainable topline growth and profitability, with TAVR growth in the mid-to-high single digits for the foreseeable future and overall company growth of 10 percent with leverage on EPS. Zovighian noted that the company's strategy is to "innovate to drive sustainable organic topline sales growth" and that R&D spending as a percentage of sales declined from nearly 19 percent in the prior year's third quarter to 18.1 percent, reflecting discipline in prioritizing R&D investments.